Fig. 8

Mechanism of HA-b-PCDA eradicates BCSCs. A-C Heatmap (A), volcano plot (B) and KEGG pathway enrichment analysis (C) of DETs of the HA-b-PCDA treated group with negative control groups (n = 3). D mRNA levels of BCSC markers analyzed by RT-qPCR. E mRNA levels of the Hippo and JAK2/STAT3 pathways analyzed by RT-qPCR. F Western blot analysis of the protein levels of BCSC markers after treatment with HA-b-PCDA for 4 d. G Quantification by densitometry analysis of (F). H Western blot analysis of protein levels of the Hippo pathway after treatment with HA-b-PCDA for 4 d. I Quantification by densitometry analysis of (H). J The cytosolic and nuclear expression of YAP1 in cells treated with HA-b-PCDA for 4 d. GAPDH and Lamin B1 were used as the loading controls. K Quantification by densitometry analysis of (J). L Western blot analysis of protein levels of the JAK2/STAT3 pathway after treatment with HA-b-PCDA for 4 d. M Quantification by densitometry analysis of (L). N Schematic diagram of the Hippo and JAK2/STAT3 pathways by which HA-b-PCDA eradicates BCSCs. “*”, p < 0.05; “**”, p < 0.01; “***”, p < 0.001